Clinical utility of high sensitivity cardiac troponin-I measurement in COVID-19 infection: a predictor of major adverse events


Cosansu K., YILMAZ S., Cosansu N. C., Gunduz H.

Kuwait Medical Journal, cilt.56, sa.2, ss.152-157, 2024 (Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 56 Sayı: 2
  • Basım Tarihi: 2024
  • Dergi Adı: Kuwait Medical Journal
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.152-157
  • Anahtar Kelimeler: COVID-19, high-sensitive troponin I, major adverse events, myocardial injury
  • Sağlık Bilimleri Üniversitesi Adresli: Hayır

Özet

Objective: Effective patient classification relies on the identification of highest-risk patients who may require more intensive supervision and support. The aim of this study was to investigate the association between in-hospital major adverse events (MAEs) and high sensitivity cardiac troponin-I (hs-cTnI) in hospitalized patients with COVID-19 infection. Design: Retrospective observational study Setting: Sakarya Education Hospital, Turkey Subjects: A cohort of 123 patients hospitalized with a diagnosis of COVID-19 was analysed. Intervention: The demographic, clinical and admission laboratory findings were collected. Main outcome measures: In-hospital MAEs were determined as the primary outcome. Results: MAEs occurred in 56.2% of the elevated hs-cTnI group and in 3.3% of the normal hs-cTnI group (P<0.001). The rates of acute pulmonary oedema (P=0.001), the need for invasive ventilation (P<0.001) and death (P<0.001) were significantly higher in the elevated hs-cTnI group. Moreover, patients with elevated hs-cTnI were more likely to have acute renal failure, acute arrhythmia and to require intensive care unit admission, non-invasive oxygen support and treatment with inotropic agents (P<0.001 for all). The multivariate regression analysis indicated that hs-cTnI independently predicts MAEs in hospitalized patients with COVID-19 (odds ratios: 35.077, 95% confidence interval: 9.035-136.181, P<0.001). In the receiver operating characteristic curve analysis, a cut-off hs-cTnI value of 21.8 was determined to predict MAEs with 81% sensitivity and 79% specificity (P<0.001). Conclusions: The hs-cTnI is an independent predictor for adverse outcomes in patients with COVID-19.